203 related articles for article (PubMed ID: 38562774)
1.
Tien JC; Chang Y; Zhang Y; Chou J; Cheng Y; Wang X; Yang J; Mannan R; Shah P; Wang XM; Todd AJ; Eyunni S; Cheng C; Rebernick RJ; Xiao L; Bao Y; Neiswender J; Brough R; Pettitt SJ; Cao X; Miner SJ; Zhou L; Wu YM; Labanca E; Wang Y; Parolia A; Cieslik M; Robinson DR; Wang Z; Feng FY; Lord CJ; Ding K; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38562774
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Wu YM; Cieślik M; Lonigro RJ; Vats P; Reimers MA; Cao X; Ning Y; Wang L; Kunju LP; de Sarkar N; Heath EI; Chou J; Feng FY; Nelson PS; de Bono JS; Zou W; Montgomery B; Alva A; ; Robinson DR; Chinnaiyan AM
Cell; 2018 Jun; 173(7):1770-1782.e14. PubMed ID: 29906450
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
[TBL] [Abstract][Full Text] [Related]
4. Pan-Cancer Analysis of
Sokol ES; Pavlick D; Frampton GM; Ross JS; Miller VA; Ali SM; Lotan TL; Pardoll DM; Chung JH; Antonarakis ES
Oncologist; 2019 Dec; 24(12):1526-1533. PubMed ID: 31292271
[TBL] [Abstract][Full Text] [Related]
5. Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series.
Iwasawa T; Kosaka T; Yasumizu Y; Hongo H; Yanai Y; Baba Y; Matsumoto K; Nakamura K; Nishihara H; Oya M
Int J Clin Oncol; 2022 Dec; 27(12):1867-1873. PubMed ID: 36271301
[TBL] [Abstract][Full Text] [Related]
6. Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.
Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L
Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807
[TBL] [Abstract][Full Text] [Related]
7. Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.
Elliott A; Zhang J; Zhang Q; Swensen J; Martin D; Xiu J; Geynisman DM; Vaena D; Herzog TJ; Holloway RW; El-Deiry WS; Spetzler D; Heath E; Stafford P; Korn WM
J Mol Diagn; 2021 Dec; 23(12):1761-1773. PubMed ID: 34562615
[TBL] [Abstract][Full Text] [Related]
8. CDK12-inactivation-induced MYC signaling causes dependency on the splicing kinase SRPK1.
Liang J; Gondane A; Itkonen HM
Mol Oncol; 2024 May; ():. PubMed ID: 38775167
[TBL] [Abstract][Full Text] [Related]
9.
Antonarakis ES; Isaacsson Velho P; Fu W; Wang H; Agarwal N; Sacristan Santos V; Maughan BL; Pili R; Adra N; Sternberg CN; Vlachostergios PJ; Tagawa ST; Bryce AH; McNatty AL; Reichert ZR; Dreicer R; Sartor O; Lotan TL; Hussain M
JCO Precis Oncol; 2020; 4():370-381. PubMed ID: 32462107
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Nguyen B; Mota JM; Nandakumar S; Stopsack KH; Weg E; Rathkopf D; Morris MJ; Scher HI; Kantoff PW; Gopalan A; Zamarin D; Solit DB; Schultz N; Abida W
Eur Urol; 2020 Nov; 78(5):671-679. PubMed ID: 32317181
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in
Chakraborty G; Patail NK; Hirani R; Nandakumar S; Mazzu YZ; Yoshikawa Y; Atiq M; Jehane LE; Stopsack KH; Lee GM; Abida W; Morris MJ; Mucci LA; Danila D; Kantoff PW
Clin Cancer Res; 2021 Mar; 27(6):1792-1806. PubMed ID: 33334906
[TBL] [Abstract][Full Text] [Related]
12. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract][Full Text] [Related]
14. Characterizing CDK12-Mutated Prostate Cancers.
Rescigno P; Gurel B; Pereira R; Crespo M; Rekowski J; Rediti M; Barrero M; Mateo J; Bianchini D; Messina C; Fenor de la Maza MD; Chandran K; Carmichael J; Guo C; Paschalis A; Sharp A; Seed G; Figueiredo I; Lambros M; Miranda S; Ferreira A; Bertan C; Riisnaes R; Porta N; Yuan W; Carreira S; de Bono JS
Clin Cancer Res; 2021 Jan; 27(2):566-574. PubMed ID: 32988971
[TBL] [Abstract][Full Text] [Related]
15.
Blee AM; He Y; Yang Y; Ye Z; Yan Y; Pan Y; Ma T; Dugdale J; Kuehn E; Kohli M; Jimenez R; Chen Y; Xu W; Wang L; Huang H
Clin Cancer Res; 2018 Sep; 24(18):4551-4565. PubMed ID: 29844131
[No Abstract] [Full Text] [Related]
16. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
[TBL] [Abstract][Full Text] [Related]
17. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
18. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.
Viswanathan SR; Ha G; Hoff AM; Wala JA; Carrot-Zhang J; Whelan CW; Haradhvala NJ; Freeman SS; Reed SC; Rhoades J; Polak P; Cipicchio M; Wankowicz SA; Wong A; Kamath T; Zhang Z; Gydush GJ; Rotem D; ; Love JC; Getz G; Gabriel S; Zhang CZ; Dehm SM; Nelson PS; Van Allen EM; Choudhury AD; Adalsteinsson VA; Beroukhim R; Taplin ME; Meyerson M
Cell; 2018 Jul; 174(2):433-447.e19. PubMed ID: 29909985
[TBL] [Abstract][Full Text] [Related]
19. Th e role of CDK12 in tumor bio logy.
Dzimková M; Procházková J; Klát J; Kohoutek J
Klin Onkol; 2020; 33(4):260-267. PubMed ID: 32894954
[TBL] [Abstract][Full Text] [Related]
20. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
Greenleaf AL
Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]